Despite triple inhaled therapy, many patients with COPD continue to experience frequent and severe exacerbations, leading to hospitalizations, symptom burden, and higher mortality risk. In this expert-led discussion, Diego J. Maselli, MD, FCCP, and Stephanie Christenson, MD, talk about personalized treatment approaches and the role of biologics in advanced COPD care.
This program is produced in partnership with the American College of Chest Physicians and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
